Redx Pharma (LON:REDX) announced its quarterly earnings results on Monday. The company reported GBX (7) (($0.09)) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of GBX (6.50) (($0.08)) by GBX (0.50) (($0.01)), Digital Look Earnings reports.

LON:REDX traded down GBX 0.25 ($0.00) during trading hours on Wednesday, reaching GBX 6.35 ($0.08). The company had a trading volume of 120,626 shares, compared to its average volume of 67,755. Redx Pharma has a 1-year low of GBX 12 ($0.16) and a 1-year high of GBX 43 ($0.56).

COPYRIGHT VIOLATION NOTICE: “Redx Pharma (REDX) Announces Earnings Results” was published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://www.dailypolitical.com/2018/11/21/redx-pharma-redx-announces-earnings-results.html.

About Redx Pharma

Redx Pharma Plc operates as a drug discovery and development company in the United Kingdom. It discovers and develops small molecule drugs for treating cancer and fibrosis. The company is developing RXC004, a porcupine inhibitor for the treatment of pancreatic, biliary, and gastric cancers, as well as melanoma; Pan-RAF inhibitor for colorectal cancer; and SHP2, a protein-tyrosine phosphatase for receptor tyrosine kinase signaling in cancer cells.

Read More: Why do companies engage in swaps?

Receive News & Ratings for Redx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.